Transforming Healthcare Access: President Donald J. Trump Unveils Groundbreaking Initiatives to Implement Most-Favored-Nation Pricing for U.S. Patients
Making Prescription Medications Affordable: In a significant announcement, President Donald J. Trump revealed today that nine prominent pharmaceutical companies have entered into agreements aimed at reducing the cost of prescription drugs for Americans. This initiative aligns drug prices with those paid by other developed nations, a strategy referred to as most-favored-nation (MFN) pricing.
- The pharmaceutical companies involved in this pivotal move include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
- These agreements will lead to price reductions for medications that manage a variety of expensive and chronic health issues, such as type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and several types of cancer, among others.
- Importantly, these agreements will extend MFN drug pricing access to every State Medicaid program across the nation, generating billions in savings and advancing President Trump’s ongoing efforts to enhance support for the most vulnerable populations.
- Additionally, these agreements ensure that foreign countries cannot exploit American innovation without contributing fairly, by applying MFN prices to all new innovative drugs introduced by these nine manufacturers.
- The agreements stipulate that these companies must redirect increased foreign revenues from existing products—boosted by the President's America First trade policies—back to benefit American patients.
- Furthermore, the agreements mandate that these companies provide medicines at significantly reduced prices when sold directly to American patients through the platform TrumpRx.
Achieving Substantial Cost Reductions: As a result of these agreements, patients can expect significant decreases in prices for many medications when they purchase directly via TrumpRx. Here are some noteworthy examples:
- Amgen will slash the price of its cholesterol medication Repatha from $573 to $239 for direct purchases through TrumpRx.
- Bristol Myers Squibb's HIV drug, Reyataz, will see a massive price drop from $1,449 to $217 when bought directly through TrumpRx.
- Boehringer Ingelheim's type two diabetes treatment, Jentadeuto, will be reduced from $525 to just $55 for TrumpRx customers.
- Genentech will reduce the price of its flu treatment, Xofluza, from $168 to $50 for those buying through TrumpRx.
- Gilead Sciences will cut the cost of its Hepatitis C treatment, Epclusa, from an eye-watering $24,920 down to $2,425 through TrumpRx.
- GSK plans to decrease the price of its inhaler range, including a fall from $265 to $89 for the widely-used asthma inhaler Advair Diskus 500/50.
- Merck will offer its diabetes drug, Januvia, at a reduced rate, dropping the cost from $330 to $100 for TrumpRx customers.
- Novartis will drastically lower the price of its Multiple Sclerosis treatment, Mayzent, from $9,987 to $1,137 when purchased via TrumpRx.
- Finally, Sanofi will make its prescription blood thinner, Plavix, available for just $16 instead of $756 through TrumpRx and will price its insulin products at $35 per month.
Strengthening National Health Security through Domestic Investment: The manufacturers participating in today’s announcements are pledging to collectively invest at least $150 billion in U.S. manufacturing in the coming years. In addition, several companies are donating essential pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), which aims to lessen reliance on foreign sources and ensure a steady supply of these products during emergencies.
- For instance, GSK is contributing 98.8 kilograms of albuterol, the active component in common rescue inhalers for asthma sufferers.
- Bristol Myers Squibb will provide tablets equivalent to 6.5 tons of apixaban—the key ingredient in Eliquis, a blood thinner used by millions of Americans.
- Merck will donate 3.5 tons of ertapenem, a critical antibacterial medication utilized for treating complex infections.
Fulfilling Commitments to Prioritize American Patients: President Trump is following through on his promises to ensure that American patients are no longer burdened with exorbitant prices that subsidize lower costs abroad—something the political establishment once deemed unattainable.
- On May 12, 2025, he enacted an Executive Order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which directed various actions to align U.S. drug prices with those of comparable countries.
- Subsequently, on July 31, 2025, President Trump reached out to leading pharmaceutical companies, outlining specific steps necessary to lower prescription drug prices in the United States to match the lowest rates found in other developed nations.
- Between September 30 and December 1, 2025, President Trump announced 14 agreements with major pharmaceutical firms aimed at bringing down prices for numerous medications relied upon by millions of Americans.
- Notably, on December 1, 2025, the Office of the United States Trade Representative, alongside the Departments of Commerce and Health and Human Services, disclosed a deal with the United Kingdom that would raise the net price of new prescription drugs by 25% in the UK, ensuring that they contribute equitably for access to innovative treatments.
What are your thoughts on these initiatives? Do you believe they will genuinely lead to lower drug prices for Americans? Let us know in the comments below!
